Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
- 15 October 2024
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5)
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with PsoriasisBioengineering, 2022
- Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case seriesJournal of the American Academy of Dermatology, 2020
- Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE studyBritish Journal of Dermatology, 2019
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsThe Lancet, 2018
- Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case seriesJAAD Case Reports, 2018